Companies › Ensem Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ETX-636 Pan-mutant-selective PI3Kα inhibitor and degrader | PIK3CA | Phase 1 | Advanced Solid Tumors | Jun 2027 |
| ETX-929 pan-KRAS inhibitor | KRAS | Phase 1 | Metastatic Colorectal Cancer (CRC) | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06993844 | ETX-636 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2027 |
| NCT07912593 | ETX-929 | Phase 1 | Metastatic Colorectal Cancer (CRC) | Oncology | Oct 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.